Market closed
Corvus Pharmaceuticals/$CRVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Corvus Pharmaceuticals
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Ticker
$CRVS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
31
ISIN
US2210151005
Website
CRVS Metrics
BasicAdvanced
$247M
-
-$0.99
-
-
Price and volume
Market cap
$247M
52-week high
$9.28
52-week low
$1.75
Average daily volume
1.3M
Financial strength
Current ratio
4.903
Quick ratio
4.773
Long term debt to equity
1.691
Total debt to equity
2.338
Management effectiveness
Return on assets (TTM)
-39.21%
Return on equity (TTM)
-100.13%
Valuation
Price to book
5
Price to tangible book (TTM)
5
Price to free cash flow (TTM)
-8.46
Growth
Earnings per share change (TTM)
92.58%
3-year earnings per share growth (CAGR)
3.63%
What the Analysts think about CRVS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Corvus Pharmaceuticals stock.
CRVS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CRVS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CRVS News
AllArticlesVideos
Why Is Corvus Pharmaceuticals Stock Soaring On Friday?
Benzinga·7 days ago
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript
Seeking Alpha·1 week ago
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Corvus Pharmaceuticals stock?
Corvus Pharmaceuticals (CRVS) has a market cap of $247M as of May 16, 2025.
What is the P/E ratio for Corvus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Corvus Pharmaceuticals (CRVS) stock is 0 as of May 16, 2025.
Does Corvus Pharmaceuticals stock pay dividends?
No, Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Corvus Pharmaceuticals dividend payment date?
Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Corvus Pharmaceuticals?
Corvus Pharmaceuticals (CRVS) does not currently have a Beta indicator.